Contact
searchSearch
HMP Global
Login

Videos

Ruth He, MD
Videos
Frontline Nivolumab Plus Ipilimumab for Patients With Unresectable Hepatocellular Carcinoma
04/15/2025
Aiwu Ruth He, MD, PhD
Ruth He, MD, PhD, discusses results from the CheckMate 9DW trial which evaluating nivolumab plus ipilimumab in the first-line setting for unresectable hepatocellular carcinoma.
Ruth He, MD, PhD, discusses results from the CheckMate 9DW trial which evaluating nivolumab plus ipilimumab in the first-line setting for unresectable hepatocellular carcinoma.
Ruth He, MD, PhD, discusses...
04/15/2025
Oncology
Videos
Molecular Residual Disease (MRD) Testing in Colorectal Cancer (CRC): Surveillance Setting (Round 3)
04/14/2025
Namrata Vijayvergia, MD, FACP; Jason A. Zell, DO, MPH
Drs Zell and Vijayvergia debate the utility of molecular residual disease (MRD) testing in the colorectal cancer (CRC) surveillance setting.
Drs Zell and Vijayvergia debate the utility of molecular residual disease (MRD) testing in the colorectal cancer (CRC) surveillance setting.
Drs Zell and Vijayvergia debate...
04/14/2025
Oncology
Videos
Molecular Residual Disease (MRD) Testing in Colorectal Cancer (CRC): Adjuvant Setting (Round 2)
04/14/2025
Namrata Vijayvergia, MD, FACP; Jason A. Zell, DO, MPH
Drs Zell and Vijayvergia debate the utility of molecular residual disease (MRD) testing in the colorectal cancer (CRC) adjuvant setting.
Drs Zell and Vijayvergia debate the utility of molecular residual disease (MRD) testing in the colorectal cancer (CRC) adjuvant setting.
Drs Zell and Vijayvergia debate...
04/14/2025
Oncology
Videos
Molecular Residual Disease (MRD) Testing in Colorectal Cancer (CRC): Neoadjuvant Setting (Round 1)
04/14/2025
Namrata Vijayvergia, MD, FACP; Jason A. Zell, DO, MPH
Drs Zell and Vijayvergia debate the utility of molecular residual disease (MRD) testing in the colorectal cancer (CRC) neoadjuvant setting.
Drs Zell and Vijayvergia debate the utility of molecular residual disease (MRD) testing in the colorectal cancer (CRC) neoadjuvant setting.
Drs Zell and Vijayvergia debate...
04/14/2025
Oncology
Videos
Molecular Residual Disease (MRD) Testing in Colorectal Cancer (CRC): Debate Introduction
04/14/2025
Yelena Y. Janjigian, MD
Given ongoing advancements in molecular residual disease (MRD) testing, should we rely on this modality to guide the diagnosis and treatment of colorectal cancer (CRC), or are we moving too fast into the unknown? Dr Janjigian provides an...
Given ongoing advancements in molecular residual disease (MRD) testing, should we rely on this modality to guide the diagnosis and treatment of colorectal cancer (CRC), or are we moving too fast into the unknown? Dr Janjigian provides an...
Given ongoing advancements in...
04/14/2025
Oncology
Alison Schram, MD, Memorial Sloan Kettering Cancer Center
Videos
Zenocutuzumab Shows Promise Among Patients With NRG1 Fusion-Positive Cancers
04/10/2025
Alison Schram, MD, discusses the results from the eNRGy trial, evaluating the bispecific antibody against HER2 and HER3, zenocutuzumab for patients with NRG1 fusion-positive cancer.
Alison Schram, MD, discusses the results from the eNRGy trial, evaluating the bispecific antibody against HER2 and HER3, zenocutuzumab for patients with NRG1 fusion-positive cancer.
Alison Schram, MD, discusses the...
04/10/2025
Oncology
Nilanjan Ghosh, MD, PhD
Videos
Advancements in Treatment Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
04/09/2025
Nilanjan Ghosh, MD, PhD
Nilanjan Ghosh, MD, PhD, FACP discusses new updates in treatment strategies for patients with relapsed/refractory diffuse large B-cell lymphoma including bispecific antibodies and CAR T-cell therapy.
Nilanjan Ghosh, MD, PhD, FACP discusses new updates in treatment strategies for patients with relapsed/refractory diffuse large B-cell lymphoma including bispecific antibodies and CAR T-cell therapy.
Nilanjan Ghosh, MD, PhD, FACP...
04/09/2025
Oncology
Sara Hurvitz, MD
Videos
Neoadjuvant and Adjuvant Treatment Options for Patients With HER2-Positive Breast Cancer
04/08/2025
Sara Hurvitz, MD
Sara Hurvitz, MD, discusses the neo/adjuvant options for patients with HER2-positive breast cancer.
Sara Hurvitz, MD, discusses the neo/adjuvant options for patients with HER2-positive breast cancer.
Sara Hurvitz, MD, discusses the...
04/08/2025
Oncology
Sameera Kumar, MD
Conference Coverage
Radiation for Patients With Stage 3 Non-Small Cell Lung Cancer
03/27/2025
Sameera Kumar, MD, highlights the role radiation plays in the treatment of patients with stage 3 non-small cell lung cancer.
Sameera Kumar, MD, highlights the role radiation plays in the treatment of patients with stage 3 non-small cell lung cancer.
Sameera Kumar, MD, highlights...
03/27/2025
Oncology
William Grady, MD
Conference Coverage
Biomarker-Based Testing vs Colonoscopy for Colorectal Cancer Screening
03/27/2025
William Grady, MD, compares biomarker-based testing and colonoscopy when considering options for colorectal cancer screening.
William Grady, MD, compares biomarker-based testing and colonoscopy when considering options for colorectal cancer screening.
William Grady, MD, compares...
03/27/2025
Oncology

Recent News

News
Tegafur-Uracil Maintenance Did Not Improve Survival for Patients With Locally Advanced Cervical Cancer
04/15/2025
Stephanie Holland
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to results from the...
04/15/2025
Oncology
News
First-Line Durvalumab Plus Platinum-Etoposide for Patients With Extensive-Stage Small Cell Lung Cancer
04/14/2025
Stephanie Holland
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
According to final efficacy and...
04/14/2025
Oncology
News
Tilsotolimod Plus Ipilimumab Fails to Significantly Improve Outcomes for Patients With Advanced Refractory Melanoma
04/11/2025
Stephanie Holland
According to results from the phase 3 ILLUMINATE-301 study, the addition of tilsotolimod to ipilimumab did not significantly improve outcomes among patients with advanced refractory melanoma.
According to results from the phase 3 ILLUMINATE-301 study, the addition of tilsotolimod to ipilimumab did not significantly improve outcomes among patients with advanced refractory melanoma.
According to results from the...
04/11/2025
Oncology
News
Cytokine and Chemokines as Predictive Biomarkers of CAR-T Therapy Outcomes in Large B-Cell Lymphoma
04/11/2025
Emily Estrada
Plasma cytokines and chemokine levels may be used as predictive biomarkers of CAR-T therapy response and toxicity among patients with large B-cell lymphoma.
Plasma cytokines and chemokine levels may be used as predictive biomarkers of CAR-T therapy response and toxicity among patients with large B-cell lymphoma.
Plasma cytokines and chemokine...
04/11/2025
Oncology
News
The Potential of Targeting NRG1 for Esophageal Squamous Cell Carcinoma
04/10/2025
Allison Casey
Targeting NRG1 may present a potential treatment strategy for esophageal squamous cell carcinoma.
Targeting NRG1 may present a potential treatment strategy for esophageal squamous cell carcinoma.
Targeting NRG1 may present a...
04/10/2025
Oncology
News
First-Line Cemiplimab Demonstrates Long-Term Efficacy Among Patients With Advanced Non-Small Cell Lung Cancer With PD-L1 ≥ 50%
04/09/2025
Stephanie Holland
According to 5-year follow-up results from the phase 3 EMPOWER-Lung 1 trial, first-line cemiplimab demonstrated continued efficacy compared to chemotherapy among patients with advanced non-small cell lung cancer with PD-L1 expression ≥ 50%.
According to 5-year follow-up results from the phase 3 EMPOWER-Lung 1 trial, first-line cemiplimab demonstrated continued efficacy compared to chemotherapy among patients with advanced non-small cell lung cancer with PD-L1 expression ≥ 50%.
According to 5-year follow-up...
04/09/2025
Oncology
News
Odronextamab Demonstrates Durability and Safety for Relapsed/Refractory DLBCL
04/09/2025
Emily Estrada
Treatment for relapsed/refractory diffuse large B-cell lymphoma with odronextamab demonstrated a manageable safety profile and durable responses among patients previously treated with 2 lines of therapy.
Treatment for relapsed/refractory diffuse large B-cell lymphoma with odronextamab demonstrated a manageable safety profile and durable responses among patients previously treated with 2 lines of therapy.
Treatment for...
04/09/2025
Oncology
News
Long-Term Real-World Efficacy of CPX-351 Therapy for Patients With High-Risk AML
04/09/2025
Emily Estrada
In a long-term, real-world analysis, CPX-351 induction therapy was significantly associated with achievement of measurable residual disease status, which was correlated with improved overall survival among patients with high-risk AML.
In a long-term, real-world analysis, CPX-351 induction therapy was significantly associated with achievement of measurable residual disease status, which was correlated with improved overall survival among patients with high-risk AML.
In a long-term, real-world...
04/09/2025
Oncology
FDA Approval
FDA Approves Nivolumab Plus Ipilimumab for Unresectable/Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer
04/08/2025
Stephanie Holland
Based on results from the CHECKMATE-8HW trial, the FDA has approved nivolumab plus ipilimumab for patients 12 years of age and older with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal...
Based on results from the CHECKMATE-8HW trial, the FDA has approved nivolumab plus ipilimumab for patients 12 years of age and older with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal...
Based on results from the...
04/08/2025
Oncology
News
First-Line Pembrolizumab With or Without Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
04/08/2025
Stephanie Holland
According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...
According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...
According to long-term follow up...
04/08/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use